The status of tuberculosis vaccine development

LK Schrager, J Vekemens, N Drager… - The Lancet Infectious …, 2020 - thelancet.com
Tuberculosis represents the leading global cause of death from an infectious agent.
Controlling the tuberculosis epidemic thus represents an urgent global public health priority …

Tuberculosis vaccine: A journey from BCG to present

S Fatima, A Kumari, G Das, VP Dwivedi - Life sciences, 2020 - Elsevier
Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease,
causing around 1.6 million deaths each year. This situation has become more complicated …

The current status, challenges, and future developments of new tuberculosis vaccines

W Gong, Y Liang, X Wu - Human vaccines & immunotherapeutics, 2018 - Taylor & Francis
Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of
death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain …

[HTML][HTML] Miliary tuberculosis: A new look at an old foe

SK Sharma, A Mohan, A Sharma - Journal of Clinical Tuberculosis and …, 2016 - Elsevier
Miliary tuberculosis (TB), is a fatal form of disseminated TB characterized by tiny tubercles
evident on gross pathology similar to innumerable millet seeds in size and appearance …

Drug-resistant TB: deadly, costly and in need of a vaccine

J Manjelievskaia, D Erck, S Piracha… - Transactions of the …, 2016 - academic.oup.com
TB is an underappreciated public health threat in developed nations. In 2014, an estimated
9.6 million TB cases and 1.5 million deaths occurred worldwide; 3.3% of these cases …

A Structural View at Vaccine Development against M. tuberculosis

M Romano, F Squeglia, E Kramarska, G Barra… - Cells, 2023 - mdpi.com
Tuberculosis (TB) is still the leading global cause of death from an infectious bacterial agent.
Limiting tuberculosis epidemic spread is therefore an urgent global public health priority. As …

Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?

F Khademi, M Derakhshan… - Expert review of …, 2018 - Taylor & Francis
Introduction: More than two billion people are latently infected with Mycobacterium
tuberculosis. Most tuberculosis (TB)-subunit vaccines currently in various stages of clinical …

Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: a systematic review and meta-analysis

CY Huang, WY Hsieh - Human vaccines & immunotherapeutics, 2017 - Taylor & Francis
Tuberculosis (TB) is a significant cause of illness and death worldwide. Immunotherapy has
been investigated in the treatment of TB. The purpose of this study was to perform a meta …

Mycobacterium tuberculosis lipoproteins in virulence and immunity – fighting with a double‐edged sword

K Becker, P Sander - FEBS letters, 2016 - Wiley Online Library
Bacterial lipoproteins are secreted membrane‐anchored proteins characterized by a lipobox
motif. This lipobox motif directs post‐translational modifications at the conserved cysteine …

A century of attempts to develop an effective tuberculosis vaccine: Why they failed?

S Soleimanpour, A Yaghoubi, FS Seddighinia… - International …, 2022 - Elsevier
Tuberculosis (TB) remains a major global health problem despite widespread use of the
Bacillus BCG vaccine. This situation is worsened by co-infection with HIV, and the …